Telix Pharmaceuticals Ltd
No SEC Form 4 filings for $TLX in the last 30 days.
See all $TLX insider activity →Talanx AG reported first-half net income up 9% to EUR 1,499 million, with growth across all divisions. Insurance revenue rose 3% (currency-adjusted) and the combined ratio improved to 88.7%. The company upgraded its full-year outlook, expecting net income to significantly exceed EUR 2.7 billion.
According to Talanx AG’s interim report dated Aug. 14, 2026, insurance revenue and net income increased. The company attributed higher operating profit to stronger investment gains and an improved combined ratio, with contributions across major segments. Talanx raised its 2026 outlook above prior targets while citing ongoing geopolitical and market risks.
Talanx AG (TLX) reported record net income of EUR 1.5bn for 6M 2026, citing strong Primary Insurance performance and investment income, along with an improved combined ratio and solid capital. The company upgraded its 2026 net income outlook to significantly above EUR 2.7bn, assuming large losses stay within budget.
Over the past 7 days, alphai's AI scored 3 news stories mentioning TLX (Telix Pharmaceuticals Ltd). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent TLX coverage spans earnings, market movers and financial news.
Upgraded full-year net income outlook tied to improved profitability metrics should support the stock versus prior guidance.
Improved underwriting and investment returns, along with a raised 2026 outlook, should support TLX earnings expectations and sentiment.
Raised 2026 earnings outlook on improved combined ratio and capital position should support the stock via higher forward profitability confidence.
The move is presented as part of the day’s top performers, but the article provides no new TLX catalyst.
Shorts appear to be easing over the month, which can reduce downside hedging pressure.
alphai scores every news story that mentions TLX with an AI model for sentiment and relevance, and aggregates insider trades from Telix Pharmaceuticals Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Talanx AG reported first-half net income up 9% to EUR 1,499 million, with growth across all divisions. Insurance revenue rose 3% (currency-adjusted) and the combined ratio improved to 88.7%. The company upgraded its full-year outlook, expecting net income to significantly exceed EUR 2.7 billion.
1 min readAccording to Talanx AG’s interim report dated Aug. 14, 2026, insurance revenue and net income increased. The company attributed higher operating profit to stronger investment gains and an improved combined ratio, with contributions across major segments. Talanx raised its 2026 outlook above prior targets while citing ongoing geopolitical and market risks.
1 min readTalanx AG (TLX) reported record net income of EUR 1.5bn for 6M 2026, citing strong Primary Insurance performance and investment income, along with an improved combined ratio and solid capital. The company upgraded its 2026 net income outlook to significantly above EUR 2.7bn, assuming large losses stay within budget.
1 min readASX 200 ended slightly lower on the day, down 0.09% to 9,263.60, but rose 3.2% for the week. Materials gained 1.32% as gold prices neared $4,300/oz. Gold and lithium stocks led, including Genesis Minerals (GMD), Capricorn Metals (CMM), Vault Minerals (VAU) and Liontown (LTR). ResMed (RMD) and 4DMedical (4DX) fell.
4 min readA weekly ASX short-selling recap (data lagged 4 days) lists the 10 most shorted stocks and the biggest changes in short interest. Healius entered the top ten, replacing Treasury Wine. Lotus Resources saw a 57.5% one-day short-interest dip after a $60m raise at 22c. Web Travel Group’s short interest fell ahead of a guidance beat and up to $90m buyback; shares rose 17.1%.
6 min readSimply Wall St reports Telix Pharmaceuticals (ASX:TLX) said in July 2026 it saw positive Phase 1 ProstACT SELECT data for TLX591-Tx, dosed the first patient in Phase 3 LUTEON for TLX250-Tx, and entered a collaboration with Regeneron. Telix raised FY26 revenue guidance to above US$1B and reported Q2 revenue of US$247M.
4 min readTelix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) will release its financial results for the half-year ended June 30, 2026 on Thursday, August 20, 2026. The Melbourne-based radiopharmaceutical company scheduled the disclosure to provide investors with timely updates on its commercial franchise and late-stage therapeutic pipeline progress during the first half of the year. An investor webcast and conference call will be held immediately following the release at 9:00 a.m.
4 min readThe article says ASX healthcare stocks fell sharply in FY26, with the Health Care sector down 36.1% and CSL, Cochlear, Resmed and Telix each down over 30% to 12 months. It compares Refinitiv consensus EPS forecasts for FY26-28 and UBS EPS estimates, noting earnings are not forecast to collapse as much as share prices. UBS cited sector picks in a 24 July 2026 note.
5 min readAustralia’s S&P/ASX 200 rose 0.72% to 8,886.1 by 1:02 p.m. AEST, up 63.1 points, after a 0.35% gain on Wednesday. The move followed Alphabet’s earnings beat, with revenue up 24% to $119.80B and Google Cloud revenue up 82% to $24.77B. Tech stocks in the index fell, while unemployment stayed at 4.4%.
7 min readTelix Pharmaceuticals shares rose 1.7% to A$15.35 after the company reported June-quarter revenue of $247 million, up 7% QoQ and 21% YoY. Precision Medicine revenue was $202 million, up 30% YoY. Telix expects FY2026 revenue and other income above $1 billion, and updated FY2026 R&D guidance to $230–$270 million, alongside progress in its LUTEON Phase 3 trial.
4 min read
